SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announced that momelotinib received Orphan Drug Designation (ODD)…

GSK plc · 6-K filed Jun 12, 2026 at 06:32 ET

At the news

BULLISHIMPACT 5/10

6-K filed Jun 12, 2026 at 06:32 ET

GSK announced that momelotinib received Orphan Drug Designation (ODD) from the FDA and EMA for VEXAS syndrome, a rare life-threatening condition with no approved treatments. The designation supports the ongoing phase II/III ATLAS trial and potential future regulatory submissions, expanding momelotinib's development program beyond myelofibrosis.

  • Momelotinib granted Orphan Drug Designation (ODD) by FDA and EMA for VEXAS syndrome.
  • VEXAS syndrome has a 30-40% five-year mortality rate and no approved treatments.
  • Phase II/III ATLAS trial evaluating momelotinib in VEXAS is underway; study design presented at EHA Congress June 11-14, 2026.
  • Momelotinib is already approved for myelofibrosis in the US, EU, UK, and Japan.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access